Gu, J., Yao, W., Shi, P., Zhang, G., Owonikoko, T. K., Ramalingam, S. S., & Sun, S. (2020). MEK or ERK inhibition effectively abrogates emergence of acquired osimertinib resistance in the treatment of EGFR-mutant lung cancers. Cancer.

Gu, Jiajia, Weilong Yao, Puyi Shi, Guojing Zhang, Taofeek K. Owonikoko, Suresh S. Ramalingam, and Shi-Yong Sun. "MEK or ERK Inhibition Effectively Abrogates Emergence of Acquired Osimertinib Resistance in the Treatment of EGFR-mutant Lung Cancers." Cancer 2020.

Gu, Jiajia, et al. "MEK or ERK Inhibition Effectively Abrogates Emergence of Acquired Osimertinib Resistance in the Treatment of EGFR-mutant Lung Cancers." Cancer 2020.